NTLA Q3 2023 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-9.6% YoY

Gross Profit

$10M80.9% margin

Operating Income

-$131M-1093.3% margin

Net Income

-$122M-1019.2% margin

EPS (Diluted)

$-1.38

QoQ Revenue Growth

-11.8%

Cash Flow

Operating Cash Flow

-$101M

Free Cash Flow

-$106M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$206M

Stockholders' Equity

$1.0B

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-9.6%
Gross Profit	$10M	-$83M	+111.6%
Operating Income	-$131M	-$106M	-24.2%
Net Income	-$122M	-$113M	-7.9%